Compare HLIO & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLIO | NEO |
|---|---|---|
| Founded | 1970 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Precision Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | 1996 | 2008 |
| Metric | HLIO | NEO |
|---|---|---|
| Price | $68.51 | $16.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 12 |
| Target Price | ★ $94.67 | $21.55 |
| AVG Volume (30 Days) | 350.8K | ★ 2.3M |
| Earning Date | 11-02-2026 | 10-27-2026 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | ★ 23.93 | N/A |
| EPS | ★ 1.25 | N/A |
| Revenue | ★ $200,727,000.00 | N/A |
| Revenue This Year | $6.91 | $10.67 |
| Revenue Next Year | $5.86 | $9.96 |
| P/E Ratio | $55.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $49.00 | $7.07 |
| 52 Week High | $95.05 | $20.15 |
| Indicator | HLIO | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 44.45 | 44.33 |
| Support Level | $66.25 | $15.72 |
| Resistance Level | $69.41 | $16.92 |
| Average True Range (ATR) | 1.78 | 0.98 |
| MACD | 0.25 | -0.34 |
| Stochastic Oscillator | 27.77 | 29.01 |
Helios Technologies Inc is an industrial technology company that develops, manufactures, and markets solutions for the hydraulics and electronics markets. It operates under two business segments: Hydraulics and Electronics. The Hydraulics segment designs and manufactures hydraulic components and systems used to transmit power and control force, speed, and motion. There are two categories based on Hydraulic system architecture: MCT and FCT. The Electronics segment provides complete, fully-tailored display and control solutions for engines, engine-driven equipment, specialty vehicles, therapy baths, and traditional and swim spas. The company generates the majority of its revenue from the Hydraulics segment. Geographically, the company generates key revenue from the Americas region.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.